{
  "symbol": "IONS",
  "company_name": "Ionis Pharmaceuticals",
  "ir_website": "https://ir.ionis.com/",
  "structured_data": [
    {
      "section_name": "Newsroom",
      "links": [
        {
          "title": "Press Releases",
          "url": "https://ir.ionis.com/newsroom/press-releases",
          "content": "[Skip to content](#lfg-main-content)\n\n[ ![Ionis Pharmaceuticals, Inc. home page](/sites/g/files/knoqqb96476/themes/site/client_site_301/dist/images/logo.png) ](https://www.ionis.com/)\n\n# Press Releases\n\nYear All20242023202220212020201920182017201620152014201320122011201020092008200720062005200420032002\n\nNov 07, 2024 \n\n[Ionis to present at upcoming investor conferences](/news-releases/news-release-details/ionis-present-upcoming-investor-conferences-14)\n\nNov 06, 2024 \n\n[Ionis Announces Pivotal Phase 3 Trial Design for ION582 in Angelman Syndrome](/news-releases/news-release-details/ionis-announces-pivotal-phase-3-trial-design-ion582-angelman)\n\nNov 06, 2024 \n\n[Ionis reports third quarter 2024 financial results](/news-releases/news-release-details/ionis-reports-third-quarter-2024-financial-results)\n\nNov 04, 2024 \n\n[Ionis announces FDA acceptance of New Drug Application for donidalorsen for prophylactic treatment of HAE](/news-releases/news-release-details/ionis-announces-fda-acceptance-new-drug-application-donidalorsen)\n\nOct 23, 2024 \n\n[Ionis to hold third quarter 2024 financial results webcast](/news-releases/news-release-details/ionis-hold-third-quarter-2024-financial-results-webcast)\n\nOct 21, 2024 \n\n[WAINZUA (eplontersen) recommended for approval in the EU by CHMP for the treatment of adults with polyneuropathy associated with hereditary transthyretin-mediated amyloidosis](/news-releases/news-release-details/wainzua-eplontersen-recommended-approval-eu-chmp-treatment)\n\nOct 03, 2024 \n\n[New positive donidalorsen data to be presented at 2024 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting](/news-releases/news-release-details/new-positive-donidalorsen-data-be-presented-2024-american)\n\nOct 01, 2024 \n\n[Zilganersen granted U.S. FDA Fast Track designation for people living with Alexander disease](/news-releases/news-release-details/zilganersen-granted-us-fda-fast-track-designation-people-living)\n\nSep 09, 2024 \n\n[Ionis announces pricing of $500.3 million public offering](/news-releases/news-release-details/ionis-announces-pricing-5003-million-public-offering)\n\nSep 09, 2024 \n\n[Ionis announces proposed public offering of common stock](/news-releases/news-release-details/ionis-announces-proposed-public-offering-common-stock)\n\nAug 28, 2024 \n\n[Ionis to present at upcoming investor conferences](/news-releases/news-release-details/ionis-present-upcoming-investor-conferences-13)\n\nAug 01, 2024 \n\n[Ionis reports second quarter 2024 financial results](/news-releases/news-release-details/ionis-reports-second-quarter-2024-financial-results)\n\nJul 22, 2024 \n\n[Ionis announces positive detailed results from the HALOS Study of ION582 in people with Angelman syndrome](/news-releases/news-release-details/ionis-announces-positive-detailed-results-halos-study-ion582)\n\nJul 19, 2024 \n\n[Ionis to hold second quarter 2024 financial results webcast](/news-releases/news-release-details/ionis-hold-second-quarter-2024-financial-results-webcast)\n\nJul 18, 2024 \n\n[Ionis completes enrollment in pivotal trial evaluating zilganersen in people living with Alexander disease](/news-releases/news-release-details/ionis-completes-enrollment-pivotal-trial-evaluating-zilganersen)\n\nJul 08, 2024 \n\n[Ionis announces webcast to report HALOS study results for ION582 in Angelman syndrome](/news-releases/news-release-details/ionis-announces-webcast-report-halos-study-results-ion582)\n\nJun 25, 2024 \n\n[Ionis announces olezarsen FCS New Drug Application accepted for Priority Review and enrollment in Phase 3 sHTG program completed](/news-releases/news-release-details/ionis-announces-olezarsen-fcs-new-drug-application-accepted)\n\nJun 18, 2024 \n\n[Ionis announces expanded licensing agreement with Otsuka in Asia Pacific for investigational medicine donidalorsen in hereditary angioedema](/news-releases/news-release-details/ionis-announces-expanded-licensing-agreement-otsuka-asia-pacific)\n\nJun 17, 2024 \n\n[Ionis to present at TD Cowen Genetic Medicines & RNA Summit](/news-releases/news-release-details/ionis-present-td-cowen-genetic-medicines-rna-summit)\n\nMay 31, 2024 \n\n[Ionis presents positive results from OASIS-HAE and OASISplus studies of investigational medicine donidalorsen in patients with hereditary angioedema](/news-releases/news-release-details/ionis-presents-positive-results-oasis-hae-and-oasisplus-studies)\n\nMay 28, 2024 \n\n[Ionis to hold donidalorsen Phase 3 data webcast](/news-releases/news-release-details/ionis-hold-donidalorsen-phase-3-data-webcast)\n\nMay 23, 2024 \n\n[New data from the Phase 3 NEURO-TTRansform study evaluating WAINUA™ (eplontersen) to be presented at the 2024 International Symposium on Amyloidosis (ISA)](/news-releases/news-release-details/new-data-phase-3-neuro-ttransform-study-evaluating-wainuatm)\n\nMay 16, 2024 \n\n[Ionis and Biogen Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis](/news-releases/news-release-details/ionis-and-biogen-announce-topline-phase-12-study-results)\n\nMay 16, 2024 \n\n[Ionis announces positive topline results from Phase 1/2a trial of ION582 for Angelman syndrome](/news-releases/news-release-details/ionis-announces-positive-topline-results-phase-12a-trial-ion582)\n\nMay 15, 2024 \n\n[Ionis to host 2024 virtual Annual Meeting of Stockholders](/news-releases/news-release-details/ionis-host-2024-virtual-annual-meeting-stockholders)\n\nMay 07, 2024 \n\n[Ionis reports first quarter 2024 financial results](/news-releases/news-release-details/ionis-reports-first-quarter-2024-financial-results)\n\nApr 25, 2024 \n\n[Ionis Publishes 2023 Corporate Responsibility Report](/news-releases/news-release-details/ionis-publishes-2023-corporate-responsibility-report)\n\nApr 23, 2024 \n\n[Ionis to hold first quarter 2024 financial results webcast](/news-releases/news-release-details/ionis-hold-first-quarter-2024-financial-results-webcast)\n\nApr 07, 2024 \n\n[Ionis presents positive results from Phase 3 Balance study of olezarsen for familial chylomicronemia syndrome](/news-releases/news-release-details/ionis-presents-positive-results-phase-3-balance-study-olezarsen)\n\nApr 01, 2024 \n\n[Ionis to present at upcoming investor conferences](/news-releases/news-release-details/ionis-present-upcoming-investor-conferences-12)\n\nMar 28, 2024 \n\n[Ionis to hold olezarsen Phase 3 data webcast](/news-releases/news-release-details/ionis-hold-olezarsen-phase-3-data-webcast)\n\nMar 25, 2024 \n\n[Positive olezarsen Phase 3 data in familial chylomicronemia syndrome to be presented at 2024 American College of Cardiology (ACC) annual meeting](/news-releases/news-release-details/positive-olezarsen-phase-3-data-familial-chylomicronemia)\n\nMar 13, 2024 \n\n[Ionis announces positive results from Phase 2 study of ION224, an investigational medicine demonstrating clinical efficacy in the treatment of NASH/MASH](/news-releases/news-release-details/ionis-announces-positive-results-phase-2-study-ion224)\n\nFeb 29, 2024 \n\n[Ionis announces new chief global product strategy officer to lead next phase of commercial growth](/news-releases/news-release-details/ionis-announces-new-chief-global-product-strategy-officer-lead)\n\nFeb 28, 2024 \n\n[Ionis to present at upcoming investor conferences](/news-releases/news-release-details/ionis-present-upcoming-investor-conferences-11)\n\nFeb 21, 2024 \n\n[Ionis reports fourth quarter and full year 2023 financial results](/news-releases/news-release-details/ionis-reports-fourth-quarter-and-full-year-2023-financial)\n\nFeb 15, 2024 \n\n[Olezarsen receives Orphan Drug designation from U.S. FDA for familial chylomicronemia syndrome](/news-releases/news-release-details/olezarsen-receives-orphan-drug-designation-us-fda-familial)\n\nFeb 08, 2024 \n\n[Eplontersen granted U.S. FDA Fast Track designation for patients with transthyretin-mediated amyloid cardiomyopathy](/news-releases/news-release-details/eplontersen-granted-us-fda-fast-track-designation-patients)\n\nFeb 07, 2024 \n\n[Ionis to hold fourth quarter and full year 2023 financial results webcast](/news-releases/news-release-details/ionis-hold-fourth-quarter-and-full-year-2023-financial-results)\n\nJan 22, 2024 \n\n[Ionis announces positive topline results from Phase 3 OASIS-HAE study of investigational donidalorsen in patients with hereditary angioedema](/news-releases/news-release-details/ionis-announces-positive-topline-results-phase-3-oasis-hae-study)\n\nJan 08, 2024 \n\n[Ionis poised for continued momentum in 2024 with product launches and key advances in robust pipeline of investigational medicines for serious diseases](/news-releases/news-release-details/ionis-poised-continued-momentum-2024-product-launches-and-key)\n"
        },
        {
          "title": "Company Statements",
          "url": "https://ir.ionis.com/newsroom/company-statements",
          "content": "[Skip to content](#lfg-main-content)\n\n[ ![Ionis Pharmaceuticals, Inc. home page](/sites/g/files/knoqqb96476/themes/site/client_site_301/dist/images/logo.png) ](https://www.ionis.com/)\n\n# Company Statements\n\nOct 07, 2023 \n\nIonis statement about results from an analysis of exploratory cardiac endpoints in the Phase 3 NEURO-TTRansform study of eplontersen \n\n[Read More](/static-files/4fb48d8a-b921-4014-83a2-93add89ac9e8)\n\nOct 07, 2023 \n\nIonis statement about results from an analysis of exploratory cardiac endpoints in the Phase 3 NEURO-TTRansform study of eplontersen \n\n[Read More](/static-files/88d0fe76-78d8-4305-840c-efe41259a7e5)\n\nJan 23, 2023 \n\nIonis’ statement about the FDA advisory committee meeting on tofersen \n\n[Read More](/static-files/c4ef84be-b943-4bee-bbbe-bbd262c59525)\n\n## We Care About Your Privacy\n\nBy clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, site registration and customization, including the use of cookies to customize our services based on your geolocation, analyze site usage, and assist in our social media and marketing efforts. For more information about our use of cookies, see[our privacy policy](https://www.ionispharma.com/privacy-policy/)\n\nManage My Cookie Settings Reject All Accept All Cookies\n\n![Company Logo](https://cdn.cookielaw.org/logos/da1ef431-04ac-4cc9-b5df-0c1fa03c9374/42ae31b2-78ed-412a-81f9-e5efc7527e7a/d5501ccf-e22a-4289-b90f-e65b749046fa/Ionis_Logo_RGB.png)\n\n## We Care About Your Privacy\n\nWhen you visit any of our websites, we may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences or your device and is mostly used to make the site work as you expect it to. The information does not usually directly identify you, but it can give you a more personalized web experience. Because we respect your right to privacy, you can choose not to allow some types of cookies. You cannot opt out of strictly necessary or functional cookies that enable our website to function properly. Click on the different category headings to find out more and change your default settings. However, blocking some types of cookies may impact your experience of the site and the services on the site we are able to customize through cookies. [Our privacy policy](https://www.ionispharma.com/privacy-policy/)\n\nAllow All\n\n###  Manage Consent Preferences\n\n#### Functional Cookies\n\nFunctional Cookies\n\nThese cookies enable the website to provide enhanced functionality and personalisation. They may be set by us or by third party providers whose services we have added to our pages. If you do not allow these cookies then some or all of these services may not function properly.\n\n#### Strictly Necessary Cookies\n\nAlways Active\n\nThese cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information.\n\n#### Performance Cookies\n\nPerformance Cookies\n\nThese cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance.\n\n#### Targeting Cookies\n\nTargeting Cookies\n\nThese cookies may be set through our site by our advertising partners. They may be used by those companies to build a profile of your interests and show you relevant adverts on other sites. They do not store directly personal information, but are based on uniquely identifying your browser and internet device. If you do not allow these cookies, you will experience less targeted advertising.\n\nBack Button\n\n### Cookie List\n\nSearch Icon\n\nFilter Icon\n\nClear\n\ncheckbox label label\n\nApply Cancel\n\nConsent Leg.Interest\n\ncheckbox label label\n\ncheckbox label label\n\ncheckbox label label\n\nReject All Confirm Settings\n\n[![Powered by Onetrust](https://cdn.cookielaw.org/logos/static/powered_by_logo.svg)](https://www.onetrust.com/products/cookie-consent/)\n"
        },
        {
          "title": "InBriefs",
          "url": "https://ir.ionis.com/newsroom/inbriefs",
          "content": "[Skip to content](#lfg-main-content)\n\n[ ![Ionis Pharmaceuticals, Inc. home page](/sites/g/files/knoqqb96476/themes/site/client_site_301/dist/images/logo.png) ](https://www.ionis.com/)\n\n# InBriefs\n\nJun 15, 2022 \n\nNew data reveal residual unmet needs in young SMA patients treated with gene therapy and suggest further potential of using SPINRAZA® \n\n[Read More](/static-files/2b03da53-0b18-4695-baa9-bc462eb1a21c)\n\nApr 29, 2022 \n\nIonis amends CARDIO-TTRansform study of eplontersen \n\n[Read More](/static-files/29b3dbb5-621d-41b9-88d8-612eeb0db0d6)\n\nMar 22, 2022 \n\nPhase 2 Study of olezarsen published in European Heart Journal \n\n[Read More](/static-files/e6b06f09-5689-41a1-ab4e-9b7f544806cf)\n\nMar 03, 2022 \n\nKey learnings from GENERATION HD1 study of tominersen highlighted at CHDI 2022 \n\n[Read More](/static-files/f0fb2c84-c1d6-43cb-91f9-169e6be41dc9)\n\nDec 27, 2021 \n\nIonis initiates HALOS clinical study of Angelman syndrome \n\n[Read More](/static-files/3a53c63f-a520-425c-92d7-f2dabcd9087c)\n\nNov 01, 2021 \n\nTopline results of Phase 2 clinical study support continued development of Cimdelirsen designed to treat uncontrolled acromegaly \n\n[Read More](/static-files/bbfabc7a-ccf2-44bb-a72d-6edba88a17e4)\n\nSep 20, 2021 \n\nASCEND study to evaluate a higher dose of Ionis-discovered nusinersen in SMA patients who had less than optimal response to Evrysdi \n\n[Read More](/static-files/d15a6e87-d7e1-4d76-8309-358347aa36ec)\n\nMay 27, 2021 \n\nIonis launches ‘Ion-ARPA’ initiative with an eye toward revolutionizing drug discovery – again \n\n[Read More](/static-files/98351462-7ea3-4724-9ec2-544007c2dd1d)\n\nApr 06, 2021 \n\nIonis expands distribution agreement with Sobi to include TEGSEDI® in North America \n\n[Read More](/static-files/08a54592-338a-4ef0-9291-bff5ea0c1d55)\n\nJan 20, 2021 \n\nION537 will be evaluated at MD Anderson in a Phase 1 study of patients with liver and head and neck cancers \n\n[Read More](/static-files/76147463-1f56-4775-991b-b1fdb0e40a92)\n\nJul 10, 2020 \n\nNew England Journal of Medicine: Results of Phase 1/2 study of tofersen, an antisense oligonucleotide, demonstrate proof-of-concept and proof-of-biology of the Ionis-created therapy to treat SOD1 familial ALS \n\n[Read More](/static-files/514af82a-0a43-4678-8eb2-418e673c489d)\n\nJun 17, 2020 \n\nLancet Gastroenterology and Hepatology: innovative antisense therapy shows potential to be safe and efficacious for the treatment of NAFLD and NASH \n\n[Read More](/static-files/abdfce17-c2a5-48ec-86a9-e95adaf8447f)\n\nMay 06, 2020 \n\nLancet Neurology: Teens and adults on SPINRAZA® showed clinically meaningful improvement in motor function \n\n[Read More](/static-files/2d4c2ed0-f458-4af6-9acb-e0f8aec80df0)\n\nMar 30, 2020 \n\nIonis Statement on COVID-19 \n\n[Read More](/static-files/33b8d567-f3de-4414-80ea-0582ccd082f1)\n\nFeb 27, 2020 \n\nIonis and partner highlight tominersen (formerly known as IONIS-HTTRx and RG6042) data at annual Huntington’s disease drug discovery conference \n\n[Read More](/static-files/f661e7fe-addd-47c8-9853-7e6d7e8e7ca9)\n\n## We Care About Your Privacy\n\nBy clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, site registration and customization, including the use of cookies to customize our services based on your geolocation, analyze site usage, and assist in our social media and marketing efforts. For more information about our use of cookies, see[our privacy policy](https://www.ionispharma.com/privacy-policy/)\n\nManage My Cookie Settings Reject All Accept All Cookies\n\n![Company Logo](https://cdn.cookielaw.org/logos/da1ef431-04ac-4cc9-b5df-0c1fa03c9374/42ae31b2-78ed-412a-81f9-e5efc7527e7a/d5501ccf-e22a-4289-b90f-e65b749046fa/Ionis_Logo_RGB.png)\n\n## We Care About Your Privacy\n\nWhen you visit any of our websites, we may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences or your device and is mostly used to make the site work as you expect it to. The information does not usually directly identify you, but it can give you a more personalized web experience. Because we respect your right to privacy, you can choose not to allow some types of cookies. You cannot opt out of strictly necessary or functional cookies that enable our website to function properly. Click on the different category headings to find out more and change your default settings. However, blocking some types of cookies may impact your experience of the site and the services on the site we are able to customize through cookies. [Our privacy policy](https://www.ionispharma.com/privacy-policy/)\n\nAllow All\n\n###  Manage Consent Preferences\n\n#### Functional Cookies\n\nFunctional Cookies\n\nThese cookies enable the website to provide enhanced functionality and personalisation. They may be set by us or by third party providers whose services we have added to our pages. If you do not allow these cookies then some or all of these services may not function properly.\n\n#### Strictly Necessary Cookies\n\nAlways Active\n\nThese cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information.\n\n#### Performance Cookies\n\nPerformance Cookies\n\nThese cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance.\n\n#### Targeting Cookies\n\nTargeting Cookies\n\nThese cookies may be set through our site by our advertising partners. They may be used by those companies to build a profile of your interests and show you relevant adverts on other sites. They do not store directly personal information, but are based on uniquely identifying your browser and internet device. If you do not allow these cookies, you will experience less targeted advertising.\n\nBack Button\n\n### Cookie List\n\nSearch Icon\n\nFilter Icon\n\nClear\n\ncheckbox label label\n\nApply Cancel\n\nConsent Leg.Interest\n\ncheckbox label label\n\ncheckbox label label\n\ncheckbox label label\n\nReject All Confirm Settings\n\n[![Powered by Onetrust](https://cdn.cookielaw.org/logos/static/powered_by_logo.svg)](https://www.onetrust.com/products/cookie-consent/)\n"
        }
      ]
    },
    {
      "section_name": "Events",
      "links": [
        {
          "title": "Events",
          "url": "https://ir.ionis.com/events",
          "content": "[Skip to content](#lfg-main-content)\n\n[ ![Ionis Pharmaceuticals, Inc. home page](/sites/g/files/knoqqb96476/themes/site/client_site_301/dist/images/logo.png) ](https://www.ionis.com/)\n\n# Events\n\n## Upcoming events\n\nDec 3, 2024 8:45 AM EST\n\n[Citi’s 2024 Global Healthcare Conference](/events/event-details/citis-2024-global-healthcare-conference)\n\n[Listen to webcast](https://kvgo.com/2024-global-healthcare-conference/ionis-pharmaceuticals-december)\n\n[Add to Outlook](/node/31871/ics)\n\n[Add to Google Calendar](https://www.google.com/calendar/render?action=TEMPLATE&text=Ionis%20Pharmaceuticals%2C%20Inc.%20-%20Citi%E2%80%99s%202024%20Global%20Healthcare%20Conference&dates=20241203T134500Z/20241203T134500Z&details=Event%20Details%3A%20https%3A//ir.ionis.com/events/event-details/citis-2024-global-healthcare-conference%0A%0AWebcast%3A%20https%3A//kvgo.com/2024-global-healthcare-conference/ionis-pharmaceuticals-december&location=&trp=false&sprop=name%3A)\n\nDec 4, 2024 9:00 AM EST\n\n[Piper Sandler 36th Annual Healthcare Conference](/events/event-details/piper-sandler-36th-annual-healthcare-conference)\n\n[Listen to webcast](https://event.webcasts.com/starthere.jsp?ei=1697135&tp_key=43d79d9e2c)\n\n[Add to Outlook](/node/31876/ics)\n\n[Add to Google Calendar](https://www.google.com/calendar/render?action=TEMPLATE&text=Ionis%20Pharmaceuticals%2C%20Inc.%20-%20Piper%20Sandler%2036th%20Annual%20Healthcare%20Conference&dates=20241204T140000Z/20241204T140000Z&details=Event%20Details%3A%20https%3A//ir.ionis.com/events/event-details/piper-sandler-36th-annual-healthcare-conference%0A%0AWebcast%3A%20https%3A//event.webcasts.com/starthere.jsp%3Fei%3D1697135&tp_key=43d79d9e2c&location=&trp=false&sprop=name%3A)\n\n## Past events\n\nNov 20, 2024 9:00 AM EST\n\n[Jefferies London Healthcare Conference](/events/event-details/jefferies-london-healthcare-conference)\n\n[Listen to webcast](https://wsw.com/webcast/jeff315/ions/1863540)\n\nNov 18, 2024 10:50 AM EST\n\n[Stifel 2024 Healthcare Conference](/events/event-details/stifel-2024-healthcare-conference)\n\n[Listen to webcast](https://wsw.com/webcast/stifel96/ions/2116710)\n\nNov 13, 2024 10:30 AM EST\n\n[Guggenheim Inaugural Healthcare Conference](/events/event-details/guggenheim-inaugural-healthcare-conference)\n\n[Listen to webcast](https://wsw.com/webcast/guggen/ions/1958805)\n\nNov 13, 2024 10:15 AM EST\n\n[UBS Global Healthcare Conference](/events/event-details/ubs-global-healthcare-conference-0)\n\n[Listen to webcast](https://cc.webcasts.com/ubsx001/111124a_js/?entity=24_DY3P2HE)\n\nNov 6, 2024 11:30 AM EST\n\n[Third Quarter 2024 Financial Results Webcast](/events/event-details/third-quarter-2024-financial-results-webcast)\n\n[Listen to webcast](https://app.webinar.net/YoVnAX8AbE8)\n\nSupporting Materials\n\n[Ionis 3Q24 Earnings Slides](/static-files/7c1f3a03-782b-4dd2-9fa6-1da0abeacf97 \"Q3_2024_Earnings Slides_FINAL \\(1\\) ionis.pdf\") 2.4 MB\n\nOct 24 - Oct 28, 2024 \n\n[American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting ](/events/event-details/american-college-allergy-asthma-immunology-acaai-annual-scientific-meeting)\n\nSupporting Materials\n\n[ACAAI_Donidalorsen Exposure-Response Analysis Hereditary Angioedema Attack Rate versus Plasma Prekallikrein Concentration Relationship](/static-files/0886784c-88d8-4f10-9e85-2c3a69e5f56b \"ACAAI_Donidalorsen Exposure-Response Analysis Hereditary Angioedema Attack Rate versus Plasma Prekallikrein Concentration Relationship.pdf\") 417.3 KB\n\n[ACAAI_Donidalorsen for Hereditary Angioedema Results from the OASISplus Open-Label Extension Study](/static-files/4048dd54-4f5b-4796-9eae-02907f4f4916 \"ACAAI_Donidalorsen for Hereditary Angioedema Results from the OASISplus Open-Label Extension Study.pdf\") 288.6 KB\n\n[ACAAI_Drug Patterns, Clinical Outcomes and Economic Costs among Hereditary Angioedema Patients Initiating Long-Term Prophylaxis](/static-files/803f7a48-e588-4c39-9c95-a90d6619b249 \"ACAAI_Drug Patterns, Clinical Outcomes and Economic Costs among Hereditary Angioedema Patients Initiating Long-Term Prophylaxis_Revised.pdf\") 215.5 KB\n\n[ACAAI_Impact of Donidalorsen on Patient-Reported Outcomes Results from the Phase 3 OASIS-HAE Study](/static-files/502906f7-f476-4b49-9e33-3cf07a87af8c \"ACAAI_Impact of Donidalorsen on Patient-Reported Outcomes Results from the Phase 3 OASIS-HAE Study.pdf\") 213.2 KB\n\n[ACAAI_Phase 2 Open-Label Extension of Donidalorsen In Patients with Hereditary Angioedema A Week 197 Analysis](/static-files/410c1936-325b-4895-bbe0-f961cf758799 \"ACAAI_Phase 2 Open-Label Extension of Donidalorsen In Patients with Hereditary Angioedema A Week 197 Analysis.pdf\") 259.6 KB\n\n[ACAAI_Treatment Of Hereditary Angioedema Safety, Efficacy, and Patient Preference after Switching to Donidalorsen (OASISplus Study)](/static-files/9119260d-95ef-40d3-9206-a275636a749a \"ACAAI_Treatment Of Hereditary Angioedema Safety, Efficacy, and Patient Preference after Switching to Donidalorsen \\(OASISplus Study\\).pdf\") 224.1 KB\n\nSep 5, 2024 12:20 PM EDT\n\n[Morgan Stanley 22nd Annual Global Healthcare Conference](/events/event-details/morgan-stanley-22nd-annual-global-healthcare-conference)\n\n[Listen to webcast](https://cc.webcasts.com/morg007/090424a_js/?entity=93_3T7OQ2X)\n\nSep 4, 2024 8:45 AM EDT\n\n[2024 Wells Fargo Healthcare Conference](/events/event-details/2024-wells-fargo-healthcare-conference)\n\n[Listen to webcast](https://cc.webcasts.com/well001/090424a_js/?entity=18_0OD0WDV)\n\nAug 1, 2024 11:30 AM EDT\n\n[Second Quarter 2024 Financial Results Webcast](/events/event-details/second-quarter-2024-financial-results-webcast)\n\n[Listen to webcast](https://app.webinar.net/3b9DAwGAaZv)\n\nSupporting Materials\n\n[Ionis 2Q24 Earnings Slides](/static-files/6425e10c-aa8c-4751-a120-6ef743ff5013 \"Q2_2024_Earnings Slides_Final \\(1\\).pdf\") 3 MB\n"
        }
      ]
    },
    {
      "section_name": "Financials",
      "links": [
        {
          "title": "SEC Filings",
          "url": "https://ir.ionis.com/financial-information/sec-filings",
          "content": "[Skip to content](#lfg-main-content)\n\n[ ![Ionis Pharmaceuticals, Inc. home page](/sites/g/files/knoqqb96476/themes/site/client_site_301/dist/images/logo.png) ](https://www.ionis.com/)\n\n# SEC Filings\n\nGroup All3,4,5Annual FilingsCurrent ReportsMergers & AcquisitionsOtherProxy FilingsQuarterly FilingsRegistration Statements\n\nFiling year All20242023202220212020201920182017201620152014201320122011201020092008200720062005200420032002200120001999199819971996\n\n[Filing Date](?items_per_page=10&order=field_nir_sec_date_filed&sort=asc \"Sort by Filing Date in ascending order\") | [Form](?items_per_page=10&order=field_nir_sec_form&sort=asc \"Sort by Form in ascending order\") | [Description](?items_per_page=10&order=field_nir_sec_description&sort=asc \"Sort by Description in ascending order\") | Filing Group | View  \n---|---|---|---|---  \nNov 14, 2024 |  [SC 13G/A](/sec-filings/sec-filing/sc-13ga/0001897612-24-001867) |  An amendment to the SC 13G filing |  Other |  [0001897612-24-001867.rtf](/static-files/2f985102-934b-44ff-82c6-fdbfe921652d) [0001897612-24-001867.pdf](/static-files/89a53217-583a-4a27-8bfc-e09f1afaf6ea)  \nNov 14, 2024 |  [4](/sec-filings/sec-filing/4/0000874015-24-000241) |  Statement of changes in beneficial ownership of securities |  3,4,5 |  [0000874015-24-000241.rtf](/static-files/eda952a9-cc5d-4a5c-8b2d-7fd771e94b3b) [0000874015-24-000241.xls](/static-files/d29972f1-8b4d-49eb-a356-f108aefc48c1) [0000874015-24-000241.pdf](/static-files/57e205c7-6136-4885-a456-d6d31d3e0803)  \nNov 14, 2024 |  [4](/sec-filings/sec-filing/4/0000874015-24-000240) |  Statement of changes in beneficial ownership of securities |  3,4,5 |  [0000874015-24-000240.rtf](/static-files/57d1330b-0b06-4f79-a18c-7f7b0e12e420) [0000874015-24-000240.xls](/static-files/2e0f9319-39b0-48c2-91c0-e0704728e69a) [0000874015-24-000240.pdf](/static-files/356f1fa8-902a-4e30-82a2-e3e56af67736)  \nNov 14, 2024 |  [4](/sec-filings/sec-filing/4/0000874015-24-000239) |  Statement of changes in beneficial ownership of securities |  3,4,5 |  [0000874015-24-000239.rtf](/static-files/32b0d453-1a65-4fdb-9d99-981c5e56d694) [0000874015-24-000239.xls](/static-files/3ad3a6ed-bdbe-4d00-8903-91d8d0577c33) [0000874015-24-000239.pdf](/static-files/25f97118-0ab6-44fa-bf54-4344141ecdb7)  \nNov 14, 2024 |  [SC 13G/A](/sec-filings/sec-filing/sc-13ga/0001193125-24-259051) |  An amendment to the SC 13G filing |  Other |  [0001193125-24-259051.rtf](/static-files/4137cf9d-61cc-4d87-8cc5-10fa9fd22a0d) [0001193125-24-259051.xls](/static-files/d7ca48af-2dd3-4028-8b55-cf43e20fb933) [0001193125-24-259051.pdf](/static-files/6689eb47-8b84-40cd-9390-16d7b5a55132)  \nNov 13, 2024 |  [144/A](/sec-filings/sec-filing/144a/0001972481-24-000285) |  Amendment to a previously filed 144 |  Other |  [0001972481-24-000285.rtf](/static-files/8757f775-9eab-42a0-9e89-d1ec0b9c8628) [0001972481-24-000285.xls](/static-files/319c3adb-a2eb-47ce-b4c8-9d0f69ee04ea) [0001972481-24-000285.pdf](/static-files/4d880142-82cc-4c3f-8eb6-aa25c8a980d0)  \nNov 12, 2024 |  [144](/sec-filings/sec-filing/144/0001972481-24-000284) |  Filed by \"insiders\" prior intended sale of restricted stock. Non-EDGAR filing |  Other |  [0001972481-24-000284.rtf](/static-files/c9357555-5933-4216-a78a-1c37a7402357) [0001972481-24-000284.pdf](/static-files/4852139a-8a0e-4ef3-8613-ab6c2004b3c9)  \nNov 12, 2024 |  [144](/sec-filings/sec-filing/144/0001972481-24-000283) |  Filed by \"insiders\" prior intended sale of restricted stock. Non-EDGAR filing |  Other |  [0001972481-24-000283.rtf](/static-files/45d7a93b-9f9b-4645-a53d-402d611ba381) [0001972481-24-000283.pdf](/static-files/61c57834-a350-4638-9f8a-5e2b69839ef4)  \nNov 12, 2024 |  [144](/sec-filings/sec-filing/144/0001972481-24-000282) |  Filed by \"insiders\" prior intended sale of restricted stock. Non-EDGAR filing |  Other |  [0001972481-24-000282.rtf](/static-files/e38dcf55-dcbd-456b-9637-fc0234e6bc6c) [0001972481-24-000282.xls](/static-files/ff200a43-c58a-4af7-9df3-509963cc08d1) [0001972481-24-000282.pdf](/static-files/96a52aa8-a00a-44bb-9965-8c434af4d7a8)  \nNov 08, 2024 |  [SC 13G](/sec-filings/sec-filing/sc-13g/0000902219-24-000487) |  A statement of beneficial ownership of common stock by certain persons |  Other |  [0000902219-24-000487.rtf](/static-files/4cf8cddb-cf7e-4a6e-95b5-04cfc1a5b590) [0000902219-24-000487.xls](/static-files/6fd1681d-1c88-4e07-b5c9-395a731c301c) [0000902219-24-000487.pdf](/static-files/17c9c950-1282-413e-a8d3-440c13219ee7)  \n  \nDisplaying 1 - 10 of 2307 results\n\nData provided by [Kaleidoscope](https://www.kscope.io).\n\n## We Care About Your Privacy\n\nBy clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, site registration and customization, including the use of cookies to customize our services based on your geolocation, analyze site usage, and assist in our social media and marketing efforts. For more information about our use of cookies, see[our privacy policy](https://www.ionispharma.com/privacy-policy/)\n\nManage My Cookie Settings Reject All Accept All Cookies\n\n![Company Logo](https://cdn.cookielaw.org/logos/da1ef431-04ac-4cc9-b5df-0c1fa03c9374/42ae31b2-78ed-412a-81f9-e5efc7527e7a/d5501ccf-e22a-4289-b90f-e65b749046fa/Ionis_Logo_RGB.png)\n\n## We Care About Your Privacy\n\nWhen you visit any of our websites, we may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences or your device and is mostly used to make the site work as you expect it to. The information does not usually directly identify you, but it can give you a more personalized web experience. Because we respect your right to privacy, you can choose not to allow some types of cookies. You cannot opt out of strictly necessary or functional cookies that enable our website to function properly. Click on the different category headings to find out more and change your default settings. However, blocking some types of cookies may impact your experience of the site and the services on the site we are able to customize through cookies. [Our privacy policy](https://www.ionispharma.com/privacy-policy/)\n\nAllow All\n\n###  Manage Consent Preferences\n\n#### Functional Cookies\n\nFunctional Cookies\n\nThese cookies enable the website to provide enhanced functionality and personalisation. They may be set by us or by third party providers whose services we have added to our pages. If you do not allow these cookies then some or all of these services may not function properly.\n\n#### Strictly Necessary Cookies\n\nAlways Active\n\nThese cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information.\n\n#### Performance Cookies\n\nPerformance Cookies\n\nThese cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance.\n\n#### Targeting Cookies\n\nTargeting Cookies\n\nThese cookies may be set through our site by our advertising partners. They may be used by those companies to build a profile of your interests and show you relevant adverts on other sites. They do not store directly personal information, but are based on uniquely identifying your browser and internet device. If you do not allow these cookies, you will experience less targeted advertising.\n\nBack Button\n\n### Cookie List\n\nSearch Icon\n\nFilter Icon\n\nClear\n\ncheckbox label label\n\nApply Cancel\n\nConsent Leg.Interest\n\ncheckbox label label\n\ncheckbox label label\n\ncheckbox label label\n\nReject All Confirm Settings\n\n[![Powered by Onetrust](https://cdn.cookielaw.org/logos/static/powered_by_logo.svg)](https://www.onetrust.com/products/cookie-consent/)\n"
        },
        {
          "title": "Annual Reports",
          "url": "https://ir.ionis.com/financial-information/annual-reports",
          "content": "[Skip to content](#lfg-main-content)\n\n[ ![Ionis Pharmaceuticals, Inc. home page](/sites/g/files/knoqqb96476/themes/site/client_site_301/dist/images/logo.png) ](https://www.ionis.com/)\n\n# Annual Reports\n\n[![2023 Annual Report](/system/files-encrypted/styles/nir_asset_small/encrypt/nasdaq_kms/assets/2024/04/24/19-00-53/2023-AR-cover.png?itok=0X3Dj2Vw) ](/static-files/aad58173-0ab5-4142-b6d4-3e940c7eb2a6)\n\n[2023 Annual Report](/static-files/aad58173-0ab5-4142-b6d4-3e940c7eb2a6)\n\n##  Previous Years \n\n[![2022 Annual Report](/system/files-encrypted/styles/nir_asset_small/encrypt/nasdaq_kms/assets/2023/04/19/20-36-15/2022-AR-cover.jpg?itok=xPgN3MFk) ](/static-files/04c7a573-2e76-42f6-9a1f-7aa000681599)\n\n[2022 Annual Report](/static-files/04c7a573-2e76-42f6-9a1f-7aa000681599)\n\n[![2021 Annual Report](/system/files-encrypted/styles/nir_asset_small/encrypt/nasdaq_kms/assets/2023/01/30/9-21-32/2021-AR-cover.jpg?itok=nLGhqTaZ) ](/static-files/2883dfed-910c-46a2-b4d0-bb0ab7f667f6)\n\n[2021 Annual Report](/static-files/2883dfed-910c-46a2-b4d0-bb0ab7f667f6)\n\n[![2020 Annual Report](/system/files-encrypted/styles/nir_asset_small/encrypt/nasdaq_kms/assets/2021/04/23/8-41-38/2020_AR.png?itok=GzBsJv8C) ](/static-files/294992c2-7d2c-49af-a863-60d3c2da97db)\n\n[2020 Annual Report](/static-files/294992c2-7d2c-49af-a863-60d3c2da97db)\n\n## We Care About Your Privacy\n\nBy clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, site registration and customization, including the use of cookies to customize our services based on your geolocation, analyze site usage, and assist in our social media and marketing efforts. For more information about our use of cookies, see[our privacy policy](https://www.ionispharma.com/privacy-policy/)\n\nManage My Cookie Settings Reject All Accept All Cookies\n\n![Company Logo](https://cdn.cookielaw.org/logos/da1ef431-04ac-4cc9-b5df-0c1fa03c9374/42ae31b2-78ed-412a-81f9-e5efc7527e7a/d5501ccf-e22a-4289-b90f-e65b749046fa/Ionis_Logo_RGB.png)\n\n## We Care About Your Privacy\n\nWhen you visit any of our websites, we may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences or your device and is mostly used to make the site work as you expect it to. The information does not usually directly identify you, but it can give you a more personalized web experience. Because we respect your right to privacy, you can choose not to allow some types of cookies. You cannot opt out of strictly necessary or functional cookies that enable our website to function properly. Click on the different category headings to find out more and change your default settings. However, blocking some types of cookies may impact your experience of the site and the services on the site we are able to customize through cookies. [Our privacy policy](https://www.ionispharma.com/privacy-policy/)\n\nAllow All\n\n###  Manage Consent Preferences\n\n#### Functional Cookies\n\nFunctional Cookies\n\nThese cookies enable the website to provide enhanced functionality and personalisation. They may be set by us or by third party providers whose services we have added to our pages. If you do not allow these cookies then some or all of these services may not function properly.\n\n#### Strictly Necessary Cookies\n\nAlways Active\n\nThese cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information.\n\n#### Performance Cookies\n\nPerformance Cookies\n\nThese cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance.\n\n#### Targeting Cookies\n\nTargeting Cookies\n\nThese cookies may be set through our site by our advertising partners. They may be used by those companies to build a profile of your interests and show you relevant adverts on other sites. They do not store directly personal information, but are based on uniquely identifying your browser and internet device. If you do not allow these cookies, you will experience less targeted advertising.\n\nBack Button\n\n### Cookie List\n\nSearch Icon\n\nFilter Icon\n\nClear\n\ncheckbox label label\n\nApply Cancel\n\nConsent Leg.Interest\n\ncheckbox label label\n\ncheckbox label label\n\ncheckbox label label\n\nReject All Confirm Settings\n\n[![Powered by Onetrust](https://cdn.cookielaw.org/logos/static/powered_by_logo.svg)](https://www.onetrust.com/products/cookie-consent/)\n"
        }
      ]
    },
    {
      "section_name": "Investor Resources",
      "links": [
        {
          "title": "Investor FAQs",
          "url": "https://ir.ionis.com/investor-resources/investor-faqs",
          "content": "[Skip to content](#lfg-main-content)\n\n[ ![Ionis Pharmaceuticals, Inc. home page](/sites/g/files/knoqqb96476/themes/site/client_site_301/dist/images/logo.png) ](https://www.ionis.com/)\n\n# Investor FAQs\n\n[Show All](#)\n\nPress space to expand and collapse this section\n\nWhere are you located?\n\nIonis Pharmaceuticals, Inc. 2855 Gazelle Court Carlsbad, CA 92010 (Carlsbad is approximately 35 miles north of downtown San Diego.)\n\nPress space to expand and collapse this section\n\nCan you provide a brief description of your Company?\n\nFor three decades, Ionis has invented medicines that bring better futures to people with serious diseases. Ionis currently has five marketed medicines and a leading pipeline in neurology, cardiology, and other areas of high patient need. As the pioneer in RNA-targeted medicines, Ionis continues to drive innovation in RNA therapies in addition to advancing new approaches in gene editing. A deep understanding of disease biology and industry-leading technology propels our work, coupled with a passion and urgency to deliver life-changing advances for patients.\n\nTo learn more about Ionis, visit [www.ionis.com](https://www.ionis.com/) and follow us on [X (Twitter)](https://x.com/ionispharma) and [LinkedIn](https://www.linkedin.com/authwall?trk=bf&trkInfo=AQEsao0QnPKvwwAAAZJyQJDYA9u710q_8GveAXwznSiHU76feHJ8GRiqfwQL8BmBNNIVN9GwcPD1n2aT_SSWRBEnt1kmEYVwcMkL2j5JwuWSGTlyMfw3MoPA9CuYaaQUNqtf2Us=&original_referer=&sessionRedirect=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fionis-pharmaceuticals). \n\nPress space to expand and collapse this section\n\nWhen was the Company founded and when did it go public?\n\nIonis Pharmaceuticals, Inc. was founded in 1989. Ionis conducted its initial public offering two years later in 1991.\n\nPress space to expand and collapse this section\n\nWhat is Ionis’ stock symbol and on what exchange is it traded?\n\nIonis is traded on the NASDAQ stock exchange under the symbol IONS. Please note that prior to December 22, 2015 our symbol was ISIS and prior to February 21, 2002 our symbol was ISIP.\n\nPress space to expand and collapse this section\n\nHow can I get a copy of your annual report?\n\nTo view a PDF file of the annual reports from 2020-2023 [click here](/financial-information/annual-reports). If you would like to receive a hard copy of any of Ionis' annual reports, please [click here](/information-request). Please note that if you are requesting that we send the annual report to an address outside of the U.S. (including Canada and Mexico) you must include your telephone number. The US Postal Service requires a phone number for shipments out of the U.S.\n\nPress space to expand and collapse this section\n\nI have lost my stock certificates. How can I replace them?\n\nContact our Transfer Agent, Equiniti Trust Company, LLC 48 Wall Street, Floor 23 New York, NY 10005 Tel 1-800-937-5449Tel 1-718-921-8124helpAST@equiniti.com\n"
        },
        {
          "title": "Settlement Information",
          "url": "https://ir.ionis.com/investor-resources/settlement-information",
          "content": "[Skip to content](#lfg-main-content)\n\n[ ![Ionis Pharmaceuticals, Inc. home page](/sites/g/files/knoqqb96476/themes/site/client_site_301/dist/images/logo.png) ](https://www.ionis.com/)\n\n# Settlement Information\n\nDelaware Chancery Court (Shumacher v. Loscalzo, et al., C.A. No. 2022-0059-LWW):\n\n[Stipulation of Settlement](/static-files/b55266df-f507-4321-be5c-890ddd3ee189)\n\n[Notice of Settlement ](/static-files/d0c89664-be58-408e-92f4-3c43acc53a24)\n\n## We Care About Your Privacy\n\nBy clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, site registration and customization, including the use of cookies to customize our services based on your geolocation, analyze site usage, and assist in our social media and marketing efforts. For more information about our use of cookies, see[our privacy policy](https://www.ionispharma.com/privacy-policy/)\n\nManage My Cookie Settings Reject All Accept All Cookies\n\n![Company Logo](https://cdn.cookielaw.org/logos/da1ef431-04ac-4cc9-b5df-0c1fa03c9374/42ae31b2-78ed-412a-81f9-e5efc7527e7a/d5501ccf-e22a-4289-b90f-e65b749046fa/Ionis_Logo_RGB.png)\n\n## We Care About Your Privacy\n\nWhen you visit any of our websites, we may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences or your device and is mostly used to make the site work as you expect it to. The information does not usually directly identify you, but it can give you a more personalized web experience. Because we respect your right to privacy, you can choose not to allow some types of cookies. You cannot opt out of strictly necessary or functional cookies that enable our website to function properly. Click on the different category headings to find out more and change your default settings. However, blocking some types of cookies may impact your experience of the site and the services on the site we are able to customize through cookies. [Our privacy policy](https://www.ionispharma.com/privacy-policy/)\n\nAllow All\n\n###  Manage Consent Preferences\n\n#### Functional Cookies\n\nFunctional Cookies\n\nThese cookies enable the website to provide enhanced functionality and personalisation. They may be set by us or by third party providers whose services we have added to our pages. If you do not allow these cookies then some or all of these services may not function properly.\n\n#### Strictly Necessary Cookies\n\nAlways Active\n\nThese cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information.\n\n#### Performance Cookies\n\nPerformance Cookies\n\nThese cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance.\n\n#### Targeting Cookies\n\nTargeting Cookies\n\nThese cookies may be set through our site by our advertising partners. They may be used by those companies to build a profile of your interests and show you relevant adverts on other sites. They do not store directly personal information, but are based on uniquely identifying your browser and internet device. If you do not allow these cookies, you will experience less targeted advertising.\n\nBack Button\n\n### Cookie List\n\nSearch Icon\n\nFilter Icon\n\nClear\n\ncheckbox label label\n\nApply Cancel\n\nConsent Leg.Interest\n\ncheckbox label label\n\ncheckbox label label\n\ncheckbox label label\n\nReject All Confirm Settings\n\n[![Powered by Onetrust](https://cdn.cookielaw.org/logos/static/powered_by_logo.svg)](https://www.onetrust.com/products/cookie-consent/)\n"
        },
        {
          "title": "Corporate Presentation",
          "url": "https://ir.ionis.com/static-files/8c906bd1-0095-4493-8260-a35762181c5b",
          "content": "\n"
        },
        {
          "title": "Investor Email Alerts",
          "url": "https://ir.ionis.com/email-alerts",
          "content": "[Skip to content](#lfg-main-content)\n\n[ ![Ionis Pharmaceuticals, Inc. home page](/sites/g/files/knoqqb96476/themes/site/client_site_301/dist/images/logo.png) ](https://www.ionis.com/)\n\n# Investor Email alerts\n\nYou may automatically receive Ionis Pharmaceuticals Inc financial information by email. To choose your options for email notification, please enter your email address below and click Submit.\n\nRequired fields denoted by an asterisk ().\n\nAlert type* Required\n\nIonis Pharmaceuticals End-of-Day Stock Quote Alert\n\nIonis Pharmaceuticals SEC Alert\n\nIonis Pharmaceuticals Calendar Alert\n\nIonis Pharmaceuticals News Alert\n\nIonis Pharmaceuticals Price & Volume Alert\n\nIonis Pharmaceuticals Report Alert\n\nEmail* Required\n\nBy clicking submit, I agree that Ionis and its subsidiaries may use the information I'm submitting to contact me with information about Investor Relations. I understand that all personal information I've submitted will be kept confidential in accordance with Ionis' [privacy policy](https://www.ionis.com/privacy-policy/) and I agree to the [terms of use](https://www.ionis.com/legal-notice/). If you no longer want to receive this information email privacy-info@ionis.com.\n\nLeave this field blank\n\nreCAPTCHA response\n\n## We Care About Your Privacy\n\nBy clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, site registration and customization, including the use of cookies to customize our services based on your geolocation, analyze site usage, and assist in our social media and marketing efforts. For more information about our use of cookies, see[our privacy policy](https://www.ionispharma.com/privacy-policy/)\n\nManage My Cookie Settings Reject All Accept All Cookies\n\n![Company Logo](https://cdn.cookielaw.org/logos/da1ef431-04ac-4cc9-b5df-0c1fa03c9374/42ae31b2-78ed-412a-81f9-e5efc7527e7a/d5501ccf-e22a-4289-b90f-e65b749046fa/Ionis_Logo_RGB.png)\n\n## We Care About Your Privacy\n\nWhen you visit any of our websites, we may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences or your device and is mostly used to make the site work as you expect it to. The information does not usually directly identify you, but it can give you a more personalized web experience. Because we respect your right to privacy, you can choose not to allow some types of cookies. You cannot opt out of strictly necessary or functional cookies that enable our website to function properly. Click on the different category headings to find out more and change your default settings. However, blocking some types of cookies may impact your experience of the site and the services on the site we are able to customize through cookies. [Our privacy policy](https://www.ionispharma.com/privacy-policy/)\n\nAllow All\n\n###  Manage Consent Preferences\n\n#### Functional Cookies\n\nFunctional Cookies\n\nThese cookies enable the website to provide enhanced functionality and personalisation. They may be set by us or by third party providers whose services we have added to our pages. If you do not allow these cookies then some or all of these services may not function properly.\n\n#### Strictly Necessary Cookies\n\nAlways Active\n\nThese cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information.\n\n#### Performance Cookies\n\nPerformance Cookies\n\nThese cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance.\n\n#### Targeting Cookies\n\nTargeting Cookies\n\nThese cookies may be set through our site by our advertising partners. They may be used by those companies to build a profile of your interests and show you relevant adverts on other sites. They do not store directly personal information, but are based on uniquely identifying your browser and internet device. If you do not allow these cookies, you will experience less targeted advertising.\n\nBack Button\n\n### Cookie List\n\nSearch Icon\n\nFilter Icon\n\nClear\n\ncheckbox label label\n\nApply Cancel\n\nConsent Leg.Interest\n\ncheckbox label label\n\ncheckbox label label\n\ncheckbox label label\n\nReject All Confirm Settings\n\n[![Powered by Onetrust](https://cdn.cookielaw.org/logos/static/powered_by_logo.svg)](https://www.onetrust.com/products/cookie-consent/)\n"
        }
      ]
    }
  ]
}